Close Menu

NEW YORK – Guardant Health said today that its Guardant360 CDx liquid biopsy test has received the CE mark for tumor mutation profiling in cancer patients with any solid tumor. The assay is also approved as a companion diagnostic to identify non-small cell lung cancer patients who may benefit from treatment with osimertinib (AstraZeneca's Tagrisso).

Guardant360 CDx is a targeted sequencing assay performed on blood samples, which detects alterations in a panel of 55 genes with established actionability in guiding the use of molecularly targeted cancer drugs.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.